,trastuzumab deruxtecan
astrazeneca,medsir,daiichi sankyo
['mbc', 'breast', 'destiny-breast04', 'medsir']
practice changing results received with roaring applause! destiny-breast04 establishes t-dxd as the new standard of care for her2-low, hr+/hr- mbc. fantastic presentation by dr. shanu mondi. #asco22 #breastcancer #metastaticbreastcancer 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc